Pregled bibliografske jedinice broj: 1227714
What may happen with melanocytic lesions during systemic melanoma treatment
What may happen with melanocytic lesions during systemic melanoma treatment // Book of asbtracts
Rim, Italija, 2021. str. 202-202 (poster, međunarodna recenzija, sažetak, stručni)
CROSBI ID: 1227714 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
What may happen with melanocytic lesions during
systemic melanoma treatment
Autori
Buljan, Marija ; Šitum, Mirna ; Filipović, Nika
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, stručni
Izvornik
Book of asbtracts
/ - , 2021, 202-202
Skup
10th World Congress of Melanoma
Mjesto i datum
Rim, Italija, 15.-17.4.2021
Vrsta sudjelovanja
Poster
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
nevi ; melanocytic lesions ; systemic therapy, pembrolizumab
Sažetak
The introduction of targeted therapy (BRAF and MEK inhibitors) and immunotherapy (anti- cytotoxic T lymphocyte antigen 4 - CTLA4 antibodies and programmed cell death protein 1- PD1 antibodies) has revolutionized the management and prognosis of patients with metastatic melanoma. These drugs are associated with a range of adverse effects, and cutaneous side effects are the most frequently observed. One of these numerous side effects include changes in melanocytic lesions which can range from changes in colour and size to development of new primary melanoma.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Ustanove:
Stomatološki fakultet, Zagreb,
KBC "Sestre Milosrdnice"
